Pathogenesis of germ cell tumor development: Application of current knowledge in early diagnostics in patient with disorders of sex development by Kaprová, Jana
1 
 
           
Univerzita Karlova v Praze 
2. lékařská fakulta 
 
Studijní program:  








MUDr. Jana Kaprová 
 
 
Patogeneze vzniku germinálních nádorů: Vyuţití současných poznatků ve 
včasné diagnostice u pacientů s poruchou pohlavního vývoje. 
 
 
Pathogenesis of germ cell tumor development: Application of current 
knowledge in early diagnostics in patients with disorders of sex development. 
 
 
Disertační práce  
 
 
Vedoucí závěrečné práce/Školitel: Prof. MUDr. Jan Lebl, CSc. 























Prohlašuji, ţe jsem závěrečnou práci zpracovala samostatně a ţe jsem řádně 
uvedla a citovala všechny pouţité prameny a literaturu. Současně prohlašuji, ţe 
práce nebyla vyuţita k získání jiného nebo stejného titulu 
Souhlasím s trvalým uloţením elektronické verze mé práce v databázi systému 
meziuniverzitního projektu Theses.cz za účelem soustavné kontroly podobnosti 
kvalifikačních prací. 
V Praze, 30. října 2013 
      Jana Kaprová 








 IDENTIFIKAČNÍ ZÁZNAM 
KAPROVÁ, Jana. Patogeneze vzniku germinálních nádorů – využití současných 
poznatků ve včasné diagnostice u pacientů s poruchou pohlavního vývoje. 
[Pathogenesis of germ cell tumor development: Application of current knowledge in 
early diagnostics in patient with disorders of sex development]. Praha, 2013. Počet 
stran 73, počet příloh 3. Disertační práce (Ph.D.). Univerzita Karlova v Praze, 2. 




















First of all I would like to express many thanks to my supervisor prof. Jan Lebl and 
my consulting supervisor as. prof. Marta Šnajderová for their guidance through my 
Ph.D. studies.   
My work would not be possible without intellectual and material support from the 
staff of the Laboratory of Experimental Patho-oncology, Department of Pathology, 
Erasmus Medical Center, Rotterdam, The Netherlands. This is namely the head of 
the laboratory prof. Leendert Looijenga, former head of the Departement and great 
specialist in gonadal pathology prof. Oosterhuis, Dr.  Eikenboom, Hans Stoop, 
Remko Hersmus and Ad Gillis, and also other students in the laboratory – Yvonne, 
Bestari, Martine, Martin, Ronak and Marcia.  
I would like to thank prof. Stenvert Drop who initiated the collaboration with 
Erasmus MC and to prof. Martine Cools who kindly invited me to take a part in the 
study on mosaicism patients. I cannot forget to give my thanks to statistician Dr. 
Lánská and to all the collaborating Czech and Dutch clinicians: Dr. Wolffenbuttel, 
Dr. Brüggenwirth, prof. Hořejší and Dr. Novotná.  
My gratitude belongs in memoriam to Dr. Zuntová, who collected majority of  the 
gonadal tissue samples from Czech patiens, and to prof. Kodet, the head of the  
Department of Pathology and Molecular Medicine, Charles University in Prague, 
2nd Faculty of Medicine and University Hospital Motol, who granted the samples 
for the studies.  
Last but not least I would like to thank all participating patients and also my family 











1. INTRODUCTION ............................................................................................................... 9 
2. THEORETICAL BACKGROUND ....................................................................................... 10 
2.1. Germ cell tumors ............................................................................................... 10 
2.2. Physiological germ cell development  ............................................................... 12 
2.3. Pathogenesis of germ cell tumors ..................................................................... 16 
2.4. Currently known immunohistochemical markers for germ cell tumors and 
precursor lesions used in the thesis .................................................................... 19 
2.5. Disorders of sex development ........................................................................... 22 
2.5.1. Definition and classification ............................................................. 22 
2.5.2. Current view on prevalence of germ cell tumors in disorders of 
sex development .............................................................................. 24 
2.5.3. DSD subtypes selected for the studies ........................................... 26 
2.5.3.1. Complete androgen insensitivity syndrome ................. 26 
2.5.3.2. 45,X/46,XY gonadal dysgenesis .................................. 27 
3. HYPOTHESES AND AIMS ................................................................................................ 29 
3.1. Study 1: Complete androgen insensitivity syndrome ......................................... 29 
3.2. Study 2: 45,X/46,XY gonadal dysgenesis ......................................................... 30 
4. MATERIAL AND METHODS .............................................................................................. 31 
4.1. Patients and histological samples ..................................................................... 31 
4.1.1. Study 1: Complete androgen insensitivity syndrome ....................... 31 
4.1.2. Study 2: 45,X/46,XY gonadal dysgenesis........................................ 33 
4.2. Methods ............................................................................................................ 34 
4.2.1. Immunohistochemistry .................................................................... 34 
4.2.2. Double-staining ............................................................................... 35 
6 
 
4.2.3. Gonadal histology assessment ....................................................... 35 
4.3. Statistics ............................................................................................................ 37 
4.3.1. Study 1: Complete androgen insensitivity syndrome ...................... 37 
4.3.2. Study 2: 45,X/46,XY gonadal dysgenesis ....................................... 37 
5. RESULTS .......................................................................................................................... 38 
5.1. Study 1: Complete androgen insensitivity syndrome ......................................... 38 
5.2. Study 2: 45,X/46,XY gonadal dysgenesis ......................................................... 45 
6. DISCUSSION .................................................................................................................... 51 
6.1. Study 1: Complete androgen insensitivity syndrome ......................................... 51 
6.2. Study 2: 45,X/46,XY gonadal dysgenesis ......................................................... 55 
7.  CONCLUSIONS................................................................................................................ 58 
8. SOUHRN ........................................................................................................................... 59 
8. SUMMARY ........................................................................................................................ 60 
9. REFERENCES .................................................................................................................. 61 
10. LIST OF AUTHOR´S PUBLICATIONS ............................................................................. 71 
10.1. Publication sources for the thesis (in extenso) ............................................... 71 
10.2. Publications without relation to the thesis (in extenso) ................................... 71 
10.3. Book chapters ................................................................................................ 72 
10.4. Abstracts ........................................................................................................ 72 









AP2-gamma  Transcription factor AP2-gamma 
AR   Androgen receptor 
CAIS    Complete androgen insensitivity syndrome 
c-KIT   A type III tyrosine kinase receptor 
DSD   Disorders of sex development 
EMS   External masculinization score 
ESC   Embryonic stem cells 
ESPE/LWPES European Society of Pediatric Endocrinology/Lawson Wilkins Pediatric  
   Endocrinology Society 
FOXL2  Forkhead transcription factor 2 
GB   Gonadoblastoma 
GBY   Gonadoblastoma locus on Y chromosome 
GCT   Germ cell tumors 
GD   Gonadal dysgenesis 
HE   Hematoxylin and eosin 
IGCNU  Intratubular germ cell neoplasia unclassified 
KITLG  c-KIT ligand (also SCF) 
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NANOG  Homeobox transcription factor NANOG 
OCT3/4  Octamer binding transcription factor 3/4 (also POU5F1) 
PAIS   Partial androgen insensitivity syndrome 
PGS   Primordial germ cells 
PLAP   Placental alkaline phosphatase 
POU5F1  POU domain class 5 transcription factor 1 (also OCT3/4) 
RSPO1  R-spondin family member 1 
SCF   Stem cell factor (also KITLG) 
SOX9   SRY-related HMG-box gene 9 
SRY   Sex-determining region on Y (also TDF) 
TDF   Testis determining factor (also SRY) 
TDS   Testicular dysgenesis syndrome 
TSPY  Testis-specific protein Y-encoded 
UGT  Undifferentiated gonadal tissue 






 1. INTRODUCTION 
 
Patients with disorders of sex development (DSD) with a specific part of Y chromosome in 
their karyotype are at a higher risk for development of gonadal Type II germ cell tumors 
(GCT), i.e., seminoma/nonseminoma in the testis and their counterparts 
dysgerminoma/nondysgerminoma in the dysgenetic gonad. According to current 
knowledge, the risk ranges between 0.8 and 60% in different DSD subgroups (Cools et al. 
2006; Page 1987). Therefore, almost all the patients undergo prophylactic gonadectomy, 
usually soon after the diagnosis is made. Gonadectomy is an invasive and psychologically 
stressing procedure, moreover, it may in some cases prevent a spontaneous course of 
puberty, and instead result in a life-long need for hormonal substitution. Thus, a crucial 
question rises, is gonadectomy necessary in all the cases? 
In this context, the aim of my thesis is to contribute to the improvement of a decision-
making process that would enable us to better determine patients with a need for 
prophylactic gonadectomy, and on the contrary, to protect others from this procedure and 
preserve their endogenous hormonal production and in some cases even fertility. Luckily, 
the recent research on pathogenesis and diagnostics of GCT has provided us with tools to 
identify not only non-invasive tumor precursors, but also premalignant lesions and germ 
cells at risk for neoplastic transformation (Looijenga et al. 2010; van de Geijn et al. 2009). 
I focused on a better determination of patients at risk within two ethiological DSD subsets. 
The first study is targeted on patients with complete form of androgen insensitivity 
syndrome (CAIS), the second study deals with patients with 45,X/46,XY gonadal 
dysgenesis (GD). Immunohistochemical detection of markers of early germ cell changes 
(especially OCT3/4 and KITLG) was applied for the purpose of the thesis. 
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2. THEORETICAL BACKGROUND 
 
2.1. Germ cell tumors 
 
GCT represent a group of neoplasms that originate from germ cells and occur throughout 
the whole life, from neonatal period to the old age. They are classified into five groups 
according to their origin and biological characteristics (Table 1). In the rest of the thesis, I 
will talk about the so called Type II GCT which the most typically reside in gonads and 
account for the most prevalent solid tumors in Caucasian men between 20 and 40 years of 
age. Lifetime risk for GCT development reaches 1% in Danish and Swiss men, in whom 
the prevalence is the highest. However, the occurrence of Type II GCT is even more 
frequent in patients with specific types of DSD (Cools et al. 2006a; Oosterhuis and 
Looijenga 2005). 
 
Table 1: Classification of germ cell tumors (adapted from Oosterhuis and Looijenga 2005). 
Type Anatomical 
site 
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Based on the morphology, Type II GCT are divided to seminomas and non-seminomas 
(i.e., yolk-sac tumor, embryonal carcinoma, choriocarcinoma, and teratoma) in the testis. 
Their counterparts in ovary and dysgenetic gonad are called dysgerminomas and non-
dysgerminomas (Cools et al. 2006a; Oosterhuis and Looijenga 2005). All testicular Type II 
GCT share a common non-invasive precursor, intratubular germ cell neoplasia unclassified 
(IGCNU, also known as carcinoma in situ of the testis) (Oosterhuis and Looijenga 2005; 
Skakkebaek 1972). The non-invasive precursor in dysgenetic gonad is termed 
gonadoblastoma (GB) (Cools et al. 2006b).  
While IGCNU is made up of neoplastic cells located within the context of seminiferous 
tubules, GB is composed of a mixture of different cell types including malignant germ cells 
and supporting (granulosa) cells arranged in well circumscribed nests (Figure 1) 
(Kersemaekers et al. 2005). Therefore, it was initially hypothesized that IGCNU and GB 
were two basically distinct entities. Later, immunohistochemical profiling of both lesions 
indicated a tight similarity of their malignant cells. The difference in overall morphology 
may be only a result of a different gonadal microenvironment. Moreover, the theory of a 
common origin of IGCNU and GB is also supported by the resemblance of the subsequent 
invasive tumors in morphology, mRNA expression, and miRNA profiling (Hersmus et al. 
2008; Gillis et al. 2007; Kersemaekers et al. 2005; Looijenga et al. 2010). 
The noticeable similarity in morphology and protein expression suggests that the 
neoplastic cells of IGCNU, GB, and invasive tumors are derived from fetal germ cells 
(primordial germ cells/gonocytes) arrested in an early stage of development (Dieckmann 





2.2. Physiological germ cell development 
 
To better explain the developmental process of GCT, it is necessary to understand specific 
basic issues of the development of gonadal tissue and germ cells themselves. Our 
knowledge in this field is mainly based on research in mice, but is (with some exceptions) 
also applicable to humans.  
Primordial germ cells (PGC) arise from embryonic stem cells (ESC) and can be detected 
in humans for the first time at week 5-6 of gestation in the yolk sac as they stain positive 
Figure 1: Intratubular germ cell neoplasia unclassified (IGCNU) and gonadoblastoma 
(GB). A - IGCNU stained with HE; B - GB stained with HE; C - IGCNU cells stained for 




for PLAP (Placental Alkaline Phosphatase) and OCT3/4 (Octamer-binding Transcription 
Factor, also termed POU5F1), among others (Hersmus et al. 2008a; Looijenga et al. 
2010). OCT3/4 is a transcription factor which is physiologically expressed only in ESC and 
PGC to provide them with ability of pluripotency, survival and proliferation (Cheng et al. 
2006; Matin et al. 2004; Niwa et al. 2000). NANOG (Homeobox Transcription Factor 
NANOG), another pluripotency regulatory transcription factor, shows similar function and 
temporospatial expression as OCT3/4 (Hart et al. 2005; Hoei-Hansen et al. 2005). 
Moreover, OCT3/4 as well as NANOG prevents PGC from apoptosis (Kehler et al. 2004; 
Yamaguchi et al. 2009).  
PGC migrate from the yolk sac along the hindgut towards the genital ridges. Among 
others, KITLG (c-KIT ligand, also know as SCF) and its tyrosine kinase receptor c-KIT are 
responsible for the proper migration, proliferation and survival. c-KIT is expressed in germ 
cells whereas KITLG serves as a chemo-attractant (Hersmus et al. 2008a; Molineaux and 
Wylie 2004). As soon as the PGC arrive to the genital ridges the structures are called 
indifferent gonads while PGC are termed gonocytes despite the unchanged morphology 
and expression profile (Looijenga et al. 2007).  
The indifferent gonad has a potential to develop either as a testis or as an ovary. Its fate 
depends on the genetic constitution, i.e., the combination of sex chromosomes (XY in 
males and XX in females) (Wilhelm et al. 2007). In the presence of the Y chromosome, 
SRY (Sex-determining region on Y, also known as TDF) expression occurs in supportive 
(pre-Sertoli) cells during human embryogenesis at week 7 of gestation and initiates the 
expression of a cascade of down-stream genes (among others SOX9) which orchestrate 
testicular differentiation (Fleming and Vilain 2004; Wilhelm et al. 2007). During this process 
pre-Sertoli cells and gonocytes form cord-like structures (sex cords), and eventually 
seminiferous tubules (Wilhelm et al. 2007). Initially, germ cells, still with characteristics of 
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gonocytes, are located in the centre of the tubules while Sertoli cells are situated at the 
periphery. Germ cells then start migrating gradually towards the periphery. Once they 
reach the basal lamina, they mature to pre-spermatogonia, their morphology changes and 
expression of gonocyte markers (OCT3/4, NANOG, AP-2gamma, PLAP, c-KIT, etc.) 
ceases (Hoei- Hansen et al. 2004; Hoei-Hansen et al. 2005; Honecker et al. 2004; Pauls et 
al. 2006). Testicular tissue of normal neonates hardly contains any OCT3/4 positive cells 
and none of these cells can be detected in infants older than 6 months (Cools et al. 2005). 
On the contrary, TSPY (Testis-specific protein Y-encoded) expression is almost exclusively 
restricted to (pre-)spermatogonia and appears firstly during the migration of the gonocytes 
towards the perifery of the tubules (Figure 2) (Honecker et al. 2004).  
In females, absence of SRY allows the differentiation towards an ovary (Fleming and Vilain 
2004; Wilhelm et al. 2007). Germ cells (oogonia) arrange in cyst-like structures with 
supportive (pre-granulosa) cells, then enter the first step of meiosis, and form primitive 
follicles. At that time they lose OCT3/4 expression, and from then on they are called 
oocytes (Figure 2) (Stoop et al. 2005; Rajpert-De Meyts et al. 2004; Wilhelm et al. 2007). 
The process is no more believed to be a simple default pathway, since several 
indispensable genes (e.g. FOXL2, WNT4, RSPO1) have been identified (Mandel et al. 
2008; Parma et al. 2006; Uhlenhaut et al. 2009). Recently, the importance of FOXL2 in 
maintenance, instead of only induction of ovarian phenotype of the gonad in mice, was 
demonstrated as the loss of FOXL2 expression leads to up-regulation of SOX9 and 
subsequently to a change of gonadal morphology, i.e., testis formation. FOXL2 and SOX9 
are expressed in supporting cells (i.e., in granulosa and Sertoli cells, respectively) in a 







Figure 2: Normal male and female gonadal differentiation. Primordial germ cells migrate 
from the yolk sac to the gonadal ridge which is  then called indifferent gonad. Subsequent 
development can follow either a male (sex cords, seminiferous tubules in the testicle) or a 
female (germ cell cysts, follicles in the ovary) differentiation pathway according to the 




2.3. Pathogenesis  of germ cell tumors  
 
Skakkebaek and co-workers postulated a clinical condition termed testicular dysgenesis 
syndrome (TDS). It is an umbrella entity for phenomena as testicular cancer, poor semen 
quality, maldescended testicles and hypospadias, which frequently coincide in a single 
patient. The rapid increase of incidence of reproductive disorders indicates that 
environmental factors are the likely cause in most of the cases, although it is supposed 
that some genetic aberrations or polymorphisms might be involved (Skakkebaek et al. 
2001; Wohlfahrt-Veje et al. 2009). The forms of DSD with increased risk for GCT 
development could be considered as an extremely escalated cases of TDS. Indeed, 
genetic background in DSD patients seems to play a major role.   
In gonads of predisposed individuals (including DSD patients) immature germ cells, which 
resemble PGC/gonocytes, persist after birth as the insufficiently differentiated supporting 
cells (Sertoli/granulosa cells) are not able to provide a satisfactory milieu to induce 
maturation to either pre-spermatogonia or oocytes. Immature germ cells can be identified 
by the positivity for factors typically expressed in early fetal germ cells (OCT3/4, PLAP, 
etc.) (Cools et al. 2005). The prolonged expression of OCT3/4 is believed to be one of the 
crucial factors in GCT development as it allows germ cells to survive and proliferate (Cools 
et al. 2009). Thanks to its similar function and temporospatial expression pattern, NANOG 
supposedly has the similar impact on tumorigenesis as OCT3/4 (Hart et al. 2005; Hoei-
Hansen et al. 2005). 
Another piece of the GCT pathogenetic puzzle seems to be an abundant expression of 
TSPY in germ cells. A special role of TSPY in human GCT development in general, but in 
DSD patients specifically, is depicted by the fact that it is the most likely candidate for the 
GBY region (Gonadoblastoma locus on Y chromosome). Existence of such a gene was 
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previously postulated by Page who based his hypothesis on genetic studies in DSD 
patients with GB or invasive tumor (Page 1987). Only patients with this part of the Y 
chromosome in their karyotype have a higher risk to develop a Type II GCT. The 
physiologic function of TSPY is not fully understood, but it is thought to be involved in 
control of germ cell mitotic proliferation in normal testis (Lau et al. 2009). In vitro TSPY 
potentiates cell proliferation by promoting cell cycle progression via cyclin B (Oram et al. 
2006).  An aberrant expression of TSPY has been related to increased proliferation of 
germ cells and to oncogenic activity (Lau 1999; Lau et al. 2000; Lau et al. 2003; Li et al. 
2007a; Li et al. 2007b; Oram et al. 2006; Tascou et al. 2003). TSPY overexpression in 
germ cells may contribute to their survival and proliferation in an unfavourable environment 
which would otherwise result in a depletion of germ cell population.  
Finally, KITLG/c-KIT system may play an important role in GCT development. KITLG is a 
ligand of the proto-oncogene c-KIT which acts as a tyrosine kinase (Strohmeyer et al. 
1995). This system is indispensable not only for fetal germ cell migration as mentioned 
above, but also for their proliferation and apoptosis as well as for regulation of adult 
spermatogonia proliferation and maintenance (Feng et al. 1999; Hoei-Hansen 2008; 
Maduit et al. 1999; Stoop et al. 2008; Strohmeyer et al. 1995). In the adult testis KITLG is 
synthesized by Sertoli cells in two splice variants: the membrane-bound form acts in 
establishing and maintenance of germ cells; the soluble form induces the testosterone 
production in Leydig cells (Maduit et al. 1999; Stoop et al. 2008). c-KIT mutations have 
been identified in numerous GCT (Biermann et al. 2007; Hoei-Hansen 2008; Looijenga et 
al. 2003a; Tian et al. 1999). Additionally, an association between specific polymorphisms 
within KITLG and the risk for Type II GCT has been reported (Kanetsky et al. 2009; Rapley 











Figure 3: Intratubular germ cell neoplasia unclassified (IGCNU) and gonadoblastoma 
(GB) development. In hypovirilization syndromes the gonad develops as a testicle, 
whereas in case of gonadal dysgenesis final morphology can vary from streak, over 
undifferentiated gonadal tissue (UGT) to a dysgenetic testicle according to the step of 
differentiation in which the development was disrupted. IGCNU arises from testicular 
tissue in which OCT3/4 positive germ cells persist and escape normal development 
while expressing TSPY at the same time. Similar persisting cells in UGT give rise to 
gonadoblastoma. Supporting cells in IGCNU and GB have characteristics of Sertoli and 




The gonad in which the IGCNU/GB or GCT arise may be of various phenotypes. IGCNU 
and (non)seminomas develop in context of testicular tissue both in normal males and 
certain types of DSD (hypovirilization syndromes and GD). GB is encountered in patients 
with GD and seems to develop mainly in context of undifferentiated gonadal tissue (UGT), 
which remarkably resembles the developmental stage of sex cords. Also streak tissue can 
harbor GB (Cools et al., 2006b). Interestingly, supporting cells in GB display significant 
FOXL2 (a marker for granulosa cells) and no or very low SOX9 (Sertoli cell marker) 
expression, indicating that GB most likely arises in the gonads which failed to follow the 
male differentiation pathway (Hersmus et al. 2008b). The highest risk for GCT 
development is attributed to UGT and to the testis displaying dysgenetic changes (Figure 
3)(Cools et al. 2009).   
 
2.4. Currently known markers for germ cell tumors and precursor lesions used in 
the thesis 
 
In the last decades several markers for detection of malignant germ cells in IGCNU/GB 
and GCT have been established (e.g. PLAP, c-KIT, OCT3/4, AP-2gamma, NANOG). None 
of them is detectable in normal gonads few months after birth (de Jong et al. 2005; Hoei-
Hansen et al. 2004; Hoei-Hansen et al. 2005; Hoei-Hansen 2008; Honecker et al. 2004; 
Jones et al. 2004; Looijenga et al. 2003b). OCT3/4 appears to be the most reliable for 
detection of IGCNU/GB cells thanks to its consistent strong nuclear staining with weak or 
no background (Figure 4A) (Cools et al. 2005; Kersemaekers et al. 2005). It serves as a 
highly specific and sensitive marker for both IGCNU/GB and pluripotent types of GCT (i.e. 
seminoma/dysgerminoma and embryonal carcinoma) (Cools et al. 2009; Looijenga et al. 
2003b).  
When assessing gonadal tissue in DSD patients, a more cautious approach should be 
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applied due to possible maturation delay of the germ cells which frequently occurs in DSD 
gonads and may lead to overdiagnosis and overtreatment (Cools et al. 2005). Immature 
germ cells express similar markers as early fetal germ cells and as IGCNU/GB cells which 
are believed to develop from them (Cools et al. 2005; Dieckmann and Skakkebaek 1999; 
Rajpert-De Meyts 2006). Cools et al. proposed additional criteria which should help to 
distinguish between maturation delay and early neoplasia in patients with hypovirilization 
syndromes (Cools et al. 2005). The criteria are based on knowledge of fetal germ cell 
development. OCT3/4 positive cells which are located in the centre of the seminiferous 
tubules and are scattered throughout the whole gonad are believed to be delayed in their 
maturation (Figure 4B) (Cools et al. 2005). On the other hand, larger number of cells 
attached to the basal lamina is considered to be abnormal and is suspicious from future 
IGCNU and GCT development. 
As mentioned above, TSPY is the most probable candidate for GBY and is abundantly 
expressed in germ cells in DSD gonads and in IGCNU/GB cells (Cools et al. 2005; 
Kersemaekers et al. 2005; Lau et al. 2009; Schnieders et al. 1996). Its expression is 
normally almost exclusively restricted to (pre-)spermatogonia (Honecker et al. 2004; Pauls 
et al. 2006). Therefore, it is only sporadically co-expressed with OCT3/4 within a single cell 
under the physiological conditions (Cools et al. 2006). Double-staining for OCT3/4 and 
TSPY is informative for the detection of cells, which escape normal development 
(Kersemaekers et al. 2005). In case of IGCNU, the OCT3/4-positive cells are attached to 
the basal lamina and may strongly co-express TSPY (Figure 4C) (Cools et al. 2006a; 
Oosterhuis et al. 2011). Double-positive cells in the luminal site are likely to be only 









Figure 4: Intratubular germ cell neoplasia unclassified (IGCNU) and delayed maturation of the 
germ cells - various immunohistochemical stainings. A - IGCNU in adult testis stained for 
OCT3/4 expression (brown), IGCNU cells are attached to the basal lamina, 100x; B - delayed 
maturation of germ cells in a testis of 10-month-old patient with complete form of androgen 
insensitivity syndrome stained for OCT3/4 expression, positive cells are located in the center 
of the tubules, 200x; C - same area as in A stained for expression of both OCT3/4 (orange) 
and TSPY (blue), IGCNU cells are mostly double-positive, 100x; D - same area as in B 
stained for expression of both OCT3/4 and TSPY, OCT3/4-positive germ cells are either 
TSPY-negative or only weakly TSPY-positive, 200x; E - same area as in A and C positive for 




KITLG seems to be a useful additional tool in distinguishing between immature germ cells 
and early malignant cells (Stoop et al. 2008, van de Geijn et al. 2009). KITLG is 
undetectable in both normal fetal and postnatal testes using immunohistochemical 
methods. However, KITLG positivity in IGCNU/GB is convincingly consistent (Figure 4E) 
(Sandlow et al. 1996; Stoop et al. 2008). KITLG staining in invasive GCT is 
heterogeneous. Interestingly, DSD gonads which harbor germ cells displaying OCT3/4 
positivity but not fulfilling the criteria for IGCNU cells (i.e., cells with maturation delay), are 
KITLG-negative (Figure 4F) (Stoop et al. 2008). This gives KITLG a unique position among 
other IGCNU/GB markers.  
 
2.5. Disorders of sex development 
 
2.5.1. Definition and classification 
 
DSD are defined as congenital conditions in which development of chromosomal, gonadal, 
or anatomical sex is atypical. The overall occurrence of genital anomalies is estimated to 
be one in 4,500 births. DSD represent a group of disorders with a highly heterogeneous 
genetic background. The very last and worldwide accepted DSD classification is a result of 
consensus made by members of ESPE/LWPES (European Society of Pediatric 
Endocrinology/Lawson Wilkins Pediatric Endocrinology Society) in Chicago in 2005. It 
divides the disorders into three subgroups according to the karyotype: i) disorders with 
aberrant sex chromosomes; ii) 46,XY DSD; iii) 46,XX DSD. Details are stated in Table 2 






Table 2: Currently used classification of DSD (adapted from Hughes et al. 2006). 







A. 47,XXY (Klinefelter 
syndrome and variants) 
A. Disorders of testicular 
development 
A. Disorders of ovarian 
development 
1. Complete or partial gonadal 
dysgenesis (e.g. SRY,SOX9, 
SF1, WT1, DHH, etc.) 
1. Gonadal dysgenesis 
2. Ovotesticular DSD 2. Ovotesticular DSD 
3. Testicular regression 3. Testicular DSD (e.g. SRY+, dup 
SOX9, RSPO1, WNT4, etc.) 
B. 45,X (Turner syndrome and 
variants) 
B. Disorders of androgen 
synthesis and action 
B. Excess of androgens 
1. Disorders of synthesis 
- mutation of LH receptor 
- Smith-Lemli-Opitz syndrome 
- mutation of StAR (Steroid acute 
  regulatory protein) 
- mutation of enzyme cleaving  
  side- chain of cholesterol  
  (CYP11A1) 
- mutation of 3β-hydroxysteroid 
  dehydrogenase 2 (HSD3B2) 
- mutation of 17α-hydroxylase/ 
  17,20-lyase (CYP17) 
- mutation of p450  
  oxidoreductase   (POR) 
- mutation 17β-hydroxysteroid 
  dehydrogenase (HSD17B3) 
- mutation 5α-reductase 2  
  (SRD5A2) 
- ect. 
1. Fetal origin 
- mutation of 3β-hydroxysteroid  
  dehydrogenase 2 (HSD3B2) 
-  mutation of 21-hydroxylase  
   (CYP21A2) 
- mutation of p450 oxidoreductase 
  (POR) 
- mutation of 11β-hydroxylase  
  (CYP11B1) 
- mutation of glucocorticoid  
  receptor  
- etc. 
2. Disorders of action 
- androgen insensitivity  
  syndrome (AR) 
- drugs and environmental  
  disruptors influencing the sex  
  development  
2. Fetoplacental origin 
- mutation of aromatase (CYP 19) 
- mutation of oxidoreductase  
  (POR) 
3. Maternal origin 
- tumors with androgen production 
- drugs with androgen action 
C. 45,X/46,XY (Mixed gonadal 
dysgenesis) 
C. Others C. Others 
1.  Disorder as a part of a 
syndrome  
(e.g. cloacal anomalies, Robinow 
sy, Aarskog sy, Hand-Foot-
Genitalia sy, etc.) 
1. Disorder as a part of a 
syndrome  
(e.g. cloacal anomalies) 
2. Syndrome of persisting 
müllerian ducts 
2. Agenesis of müllerian duct  
structures 
3. Vanishing testis syndrome 3. Uterus anomalies  
(e.g. MODY5) 




5. Labial adhesions 
6. Cryptorchidism 
7. Environmental influences 







2.5.2. Current view on prevalence of germ cell tumors in disorders of sex 
development  
 
As mentioned above, only patients carrying GBY region in their karyotype  are endangered 
by GCT development (Page 1987; Lau et al. 2009). Multiple studies endeavour to 
establish the risk for GCT in particular DSD subgroups. However, one has to reckon with 
bias due to i) inconsistent DSD classifications ii) inaccurate DSD diagnostics iii) 
heterogeneous criteria for IGCNU/GB diagnosis iv) possibly preferential reporting of tumor 
cases v) lower incidence of malignancies in later series due to early prophylactic 
gonadectomy. 
In the last few years, the most extensive meta-analysis was performed by Cools and 
colleagues (Cools et al. 2006a). They divided DSD patients into several risk groups for 
development of Type II GCT. Patients with hypovirilization syndromes have a normal male 
karyotype and their gonads develop into normal testicles. These disorders are caused by a 
defect in either synthesis or action of androgens. The most numerous are patients with 
androgen insensitivity syndrome.  
The overall prevalence of IGCNU and invasive GCT in this group is estimated to be 5.5%. 
There is, however, an important difference between patients with complete (CAIS) and 
partial (PAIS) androgen insensitivity syndrome in which malignancies occur in 0.8% and 
15%, respectively (Cools et al. 2006a). Other hypovirilization syndromes are very rare. 
Malignancies in 17% of patients with 17β-hydroxysteroid dehydrogenase were mentioned 
in one small series (Cools et al. 2005), while only one case of seminoma in a patient with 
5α-reductase deficiency and no tumors in patients with Leydig cell hypoplasia have been 
reported so far (Cools et al. 2005; Sasaki et al. 2003).  
Patients with gonadal dysgenesis (with either a 46,XY or 45,X/46,XY karyotype) seem to 
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be the most endangered subgroup, although the prevalence in different series is rather 
incoherent being reported in 15-100% of cases (Cools et al. 2006a; Slowikowska-Hilczer 
et al. 2001). After the rational interpretation of the available data, Cools et al. rated the total 
occurrence at 12%, and possibly more than 30% if gonadectomy would not have been 
performed. Particularly in patients with mosaic karyotype the prevalence ranges between 
15 and 40%, while in those with 46,XY karyotype it reaches approximately 30% (Cools et 
al. 2006a). In a series of patients with a defect of the WT1 gene, malignancies were 
reported in 60% of patients with Frasier syndrome (Joki-Erkkilä et al. 2002) and in 40% of 
patients with Denys-Drash syndrome (Pelletier et al. 1991).  
In patients with ovotesticular DSD, previously referred to as true hermaphroditism, the 
occurrence of neoplasia is estimated at 2.6% (Table 3) (Cools et al. 2006). 
 
 




Risk Type of DSD Prevalence 
High GD in general 
46,XY GD 
      Frasier syndrome 
















Leydig cell hypoplasia 
? 
? 
GD – gonadal dysgenesis; CAIS – complete androgen insensitivity syndrome; PAIS – 
partial androgen insensitivity syndrome; * might reach more than 30%, if gonadectomy 





2.5.3. DSD subtypes selected for the studies 
 
2.5.3.1. Complete androgen insensitivity syndrome 
 
Androgen insensitivity syndrome is caused by an inactivating mutation in androgen 
receptor (AR) gene. It is an X-linked recessive disorder and thus affects only 46,XY 
individuals (Galani et al. 2008; Hughes et al. 2012). Overall incidence is estimated to be 
1:40,800-99,000 (Boehmer et al. 2001). Clinical presentation may vary between normal 
infertile male and female with blindly ended vagina and missing internal genitalia. Gonads 
have a character of testis in all cases. Phenotypical variability led to a subdivision of the 
syndrome into mild/minimal, partial and complete form (Quigley et al. 1995). Patients with 
CAIS are raised as girls and are usually recommended for gonadectomy. As it has been 
stressed before, this procedure prevents spontaneous pubertal development, if provided in 
childhood, and leads to a need for hormonal substitution. 
Typical changes in gonadal histology of patients with CAIS have been described. They 
develop with rising age and may be influenced by two major factors: abnormal gonadal 
location and decreased AR activity (Giwercman et al. 1989; Hannema et al. 2006). 
However, precise contribution of the factors is not yet fully elucidated.  
Among others, germ cell anomalies are of crucial importance. The occurrence of GCT has 
been reported to be up to 22% in adult patients in different studies (Deans et al. 2012). 
Invasive GCT are very rare in childhood and adolescence (Hurt et al. 1989); however, non-
invasive precursor lesions characterized as IGCNU have been repeatedly described in this 
age group (Cools et al. 2005; Hannema et al. 2006). Interestingly, the occurrence of 
IGCNU in pediatric patients, which was present at a maximum of 6% of cases, does not 
reach the frequency of GCT in adulthood, reported in most literature (Cools et al. 2005; 
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Hannema et al. 2006; Cassio et al. 1990; Müller and Skakkebaek 1984; Bangsbøll et al. 
1992).   
The prevalence of IGCNU appears to be remarkably higher (15%) in pediatric patients with 
PAIS than in patients with CAIS (Cools et al. 2006a). Hannema and colleagues described 
that the expected residual activity of AR has a positive effect on the development of 
Wolffian structures and the enlargement of seminiferous tubules during puberty in patients 
with CAIS (Hannema et al. 2004; Hannema et al. 2006). Whether the residual AR activity 
also has an impact on the survival of normal and/or atypical germ cells has not yet been 
reported.  
 
2.5.3.2. 45,X/46,XY gonadal dysgenesis 
 
Sex chromosome mosaicism (45,X/46,XY and variants) occurs with an estimated 
incidence of 1,5/10 000 (Chang et al. 1990) and may be due to loss of the Y chromosome 
through anaphase lag or to interchromosomal rearrangements with final loss of a 
structurally abnormal Y chromosome. The clinical spectrum is highly heterogeneous, with 
no obvious correlation between the phenotypic appearance and the respective cell line 
counts on routine peripheral blood karyotyping (Chang et al. 1990; Grumbach et al. 2003; 
Telvi et al. 1999) or even on the basis of gonadal cell line counts (Cools et al. 2007). Up to 
95% of individuals may live undiagnosed as normal males (Chang et al. 1990). However, 
ambiguous genitalia in a newborn, but also mild undervirilization (e.g. hypospadias) in 
boys or even typical Turner syndrome in girls may be associated with 45,X/46,XY 
mosaicism (Telvi et al. 1999).  
Because of the presence of GBY in their karyotype, the patients are endangered by 
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aberrant expression of TSPY and consequently by increased tumor risk. The recent 
change in attitude towards clinical management of DSD patients, with increased emphasis 
on a conservative approach and the delay of irreversible surgery until adulthood (Hughes 
et al. 2006; Hughes 2010; Wiesemann et al. 2010; Creighton et al. 2004) has brought 
along uncertainty concerning the optimal approach with regard to gonads at risk for 
malignant transformation, e.g. in individuals with 45,X/46,XY mosaicism and male gender. 
Evidently, gonadectomy is not the treatment of choice in these patients, but on the basis of 
a review of the relevant literature, tumor risk in 45,X/46,XY individuals has been reported 
to be around 15% (Cools et al. 2006a). However, clinical experience suggests a much 
lower incidence in 45,X/46,XY Turner syndrome girls. On the other hand, recent research 
has identified UGT, for which 45,X/46,XY is a known risk factor, as the precursor lesion for 













3. HYPOTHESES AND AIMS 
 
3.1. Study 1: Complete androgen insensitivity syndrome 
 
Impaired gonadal position and androgen action very likely cause histopathological 
changes of the gonads in CAIS, however, precise contribution of the two factors has never 
been elucidated. With respect to the fact that risk of development of gonadal GCT in PAIS 
is strikingly higher than in CAIS, patients with CAIS and residual AR activity may have 
higher tumor risk than CAIS patients with no AR activity.  
 
Hypothesis: 
1. Level of AR activity and gonadal position influence the histopathological changes in 
gonads of patients with CAIS. 
2. CAIS patients with expected residual AR activity are at higher risk of GCT 
development than patiens with no residual activity of AR. 
 
Aims: 
1. To assess gonadal histology including germ cell pathology in patients with CAIS. 





3.2. Study 2: 45,X/46,XY gonadal dysgenesis 
 
Clinical experience in patients with 45,X/46,XY mosaicism indicates that there exist 
differences in risk for development of gonadal GCT between individuals with different 
phenotypes. However, evidence based work is missing. 
 
Hypothesis:  




1. To assess the level of masculinization of 45,X/46,XY individuals. 
2. To assess the gonadal type and presence of (pre-)malignant germ cells in gonads of 
the subjects. 








4. MATERIAL AND METHODS 
 
4.1. Patients and histological material 
 
4.1.1. Study 1: Complete androgen insensitivity syndrome 
 
We investigated 37 testes from 19 patients with the complete form of androgen 
insensitivity syndrome, i.e., patients with an unambiguously female phenotype who were 
diagnosed based on having AR gene mutation identified by direct sequencing in a 
diagnostic set up. Patients ranged in age from 3 months to 18.5 years (mean = 9.2 years). 
The samples were included only if the activity of AR could be inferred from the sequencing 
results or if a reference about the functional studies existed. Based on the type of mutation 
(frame shift mutations, mutations leading to the introduction of a stop codon after internal 
initiation-of-translation sites) and a search of the literature (point mutations with zero 
activity in ligand-binding or transactivation studies), no residual activity of AR was 
expected in 11 patients (Brüggenwirth et al. 1996; Brüggenwirth et al. 1998; Mowszowitz et 
al. 1993; Weidemann et al. 1996). In 5 patients, a point mutation in the ligand-binding 
domain resulted in a mutated AR with some residual activity in transactivation studies 
(Hannema et al. 2004; Knoke et al. 1999; Beitel et al. 1994; Marcelli et al. 1994). In the 
remaining 3 patients, the activity of AR was uncertain: mutation of an intronic region led to 
abnormal splicing of AR in one sibling pair (Brüggenwirth et al. 1997); AR truncated at the 
amino terminal side was detected as a result of an early introduced stop-codon in the third 
case (Zoppi et al. 1993). One or both gonads were originally positioned in the inguinal 
region in 6 patients and were relocated into the abdominal cavity at hernioplasty during 
infancy or early childhood. Only a single gonad was situated in the labial region and was 
grouped with inguinal gonads for statistical analysis (Table 4). The gonads were removed 
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as a prophylactic measure in all cases.  
This study was approved by the local Ethics Committee of the University Hospital Motol, 
Prague (EC 237/2009), and the samples were used according to the Code for Proper 
Secondary Use of Human Tissue in The Netherlands, as developed by the Dutch 
Federation of Medical Scientific Societies (Federa, 2011). 
 
Table 4: Patients information for age, mutation (Reference sequence: hg19, NM 000044) 





nucleotide (HGVS)//amino acid level 


























































































Sister of S9 
c.1769-11T>A//p.? 








Sister of S4 
c.2197G>A//Asp733Asn 
Sister of S17 
c.832-833dupGC//p.Val279Leufs*18 






Sister of S15 
c.2546dupA//p.Asn849Lysfs*32 




Sister of S10 
c.832-833dupGC//p.Val279Leufs*18 
Sister of S11 
c.159-171del13//p.Leu54Serfs*117 
??? 
TA (0% activity with 10 nM R1881) 
No 
LBA (0% ligand binding activity)  
No 




TA (0% activity with 10 nM R1881) 
Yes 
TA (100% activity with 3 nM R1881) 
??? 
TA (30% with 2 nM DHT) 
Yes 








TA (0% activity with 10 nM mibolerone) 
Yes 





















et al. 1997 
Knoke et al. 
1999 
Zoppi et al. 
1993 









et al. 1993 



































































i/a (1 y) 
i/a (1 y) 
i/a (6 y) 






i/a (0 y) 




i/a (1 y) 
i/a (1 y) 
i/a (3 y) 
i/a (3 y) 
abdominal 
abdominal 
TA- transactivation; LBA - ligand binding activity; ??? - uncertain; i/a (x y) - original location 




4.1.2. Study 2: 45,X/46,XY gonadal dysgenesis 
 
Eighty seven gonadal tissue samples from 48 patients with 45,X/46,XY (or variants) GD, 
obtained by biopsy or gonadetomy, were available. Clinical data were recorded by treating 
physicians and reviewed. An overview of the patients and samples is provided in Table 5. 
The group of individuals with female phenotype is overrepresented which probably relates 
to the finding that most 45,X/46,XY cases live undiagnosed as normal males (Chang et al. 
1990). Surgery is delayed in this group due to later diagnosis (mostly because of short 
stature) than in groups with mild undervirilization and ambiguous phenotype. Eighty four 
gonadal samples were considered for further analysis; one sample was excluded because 
it was a gonadectomy specimen of a previously biopsied gonad and revealed no new 
findings. In one patient who received a left biopsy and a right gonadectomy clinical 
information was insufficient.  
Patients were classified into three groups, based on the EMS (External masculinization 
score), which represents a clinical scoring system (based on the position of the gonads, 
length of the phallus, presence of scrotal fusion and position of the urethral meatus) to 
quantitatively assess the degree of undervirilization in DSD patients (Ahmed et al. 2000). 
The EMS was calculated from data of the first clinical presentation: Group 1: mild 
undervirilization, EMS 7-12, Group 2: ambiguous phenotype, EMS <7, and Group 3: 
female phenotype, representing in fact girls with Turner syndrome (without clitoromegaly).  
The study was approved by the medical ethical committees of the University Hospital 
Ghent (MEC 2008/098), the Erasmus Medical Center Rotterdam (MEC 02.981) and the 
Ethics Committee of the University Hospital Motol, Prague (EC 237/2009). The samples 
were used according to the “Code for Proper Secondary Use of Human Tissue in the 
Netherlands”, as developed by the Dutch Federation of Medical Scientific Societies 
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(FMWV) (version 2011). 










Patients 10 14 23 











Mean age at 
surgery (years) 
4.0 2.2 12.2 










All gonadal samples were fixed in 10% formalin for 24 hours and embedded in paraffin. 
After antigen retrieval (120°C, 0.9 Bar), 3 to 4-μm-thick sections were evaluated for the 
presence of OCT3/4 (sc-5279, Santa Cruz Biotechnology, CA, USA, dilution 1:350-1000, 
incubated 120' at room temperature), TSPY (the antibody was kindly provided by prof. Dr. 
C. Lau, Department of Medicine, VA Medical center, University of California, San 
Francisco, CA, USA; dilution 1:3000-4000, incubated overnight at 4°C), and KITLG (sc-
1302, Santa Cruz Biotechnology, CA, USA, dilution 1:250-500, incubated overnight at 
4°C). Detection and visualization was conducted using biotinylated secondary antibodies 
and avidin-biotin-complex conjugated with horseradish peroxidase for OCT3/4 (Vectastain 
ABC kit Elite pk-6100 Standard) or alkaline phosphatase for TSPY and KITLG (Vectastain 
ABC kit pk-5000 AP). Diaminobenzidine/H2O2 (for OCT3/4) and New Fuchsine/Naphtol 
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ASMX phosphate (for TSPY and KITLG; N500 Sigma, Steinheim, Germany) were used as 
substrates. Adult testicular tissue with IGCNU was used as a positive control for all 
staining.  
In case of Study 1, tissue samples from 36 gonads (22 gonads from patients lacking AR 
activity; 9 gonads from patients with expected residual AR activity; 5 gonads from patients 
with uncertain AR activity) were available for immunohistochemical staining.  
All included samples were available for the staining in Study 2. 
 
4.2.2. Double-staining  
 
Samples with OCT3/4-positive cells were investigated for co-expression of OCT3/4 and 
TSPY. Sections were pretreated with H2O2, pressure cooked and incubated with primary 
antibodies against TSPY (overnight, at 4°C) and OCT3/4 (sc-8629, dilution 1:350, 
incubated 120' at room temperature). TSPY was detected using the avidin-biotin-complex 
conjugated with alkaline phosphatase complex and Fast Blue/Naphtol ASMX phosphate as 
a substrate. OCT3/4 was detected with avidin-biotin-complex conjugated with horseradish 
peroxidase complex and 3-amino-9-ethyl-carbazole (Sigma, Steinheim, Germany)/H2O2 as 
a substrate. In between the two stainings, free biotin was blocked (Vector Laboratories, 
Burlingame, CA USA). The adult testicular tissue containing IGCNU was used as positive 
control. This technique was performed only in Study 1. 
 
4.2.3. Gonadal histology assessment 
 
Study 1: At least one section from each gonad was stained with hematoxylin and eosin 
(HE) and assessed for overall organization of the gonadal tissue, markers of pubertal 
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maturation, and abnormal histological phenomena. The fraction of seminiferous tubules 
containing germ cells was calculated in at least 200 cross-sections of tubules in each 
gonad. The proportion of OCT3/4-positive cells allocated to the basal lamina was 
assessed on twenty cross-sections of tubules, if available. 
Delayed maturation of germ cells was defined as a presence of OCT3/4-positive germ 
cells with round nuclei located centrally in the seminiferous tubules of individuals over 6 
months of age. Only occasionally are weakly OCT3/4-positive cells at the basement 
membrane of the tubules accepted as indicators of delayed maturation. Such cells are 
considered to be in the process of turning off OCT3/4 expression. KITLG is not expressed 
in gonads with delayed maturation germ cells (Cools et al. 2005; Stoop et al. 2008). For 
the diagnosis of IGCNU, the presence of at least one cross-section of a seminiferous 
tubule containing a homogeneous population of atypical germ cells with angulated nuclei 
was required. These cells must show either homogeneous double expression of OCT3/4 
(nuclear) and TSPY (cytoplasmic and membranous) or homogenous expression of 
OCT3/4 (nuclear) in the absence of TSPY. The involved tubule must show expression of 
KITLG, which usually presents as irregular spots associated with the cytoplasm of Sertoli 
cells. A diagnosis of pre-IGCNU was made when the findings fall short of the criteria for 
IGCNU and are beyond those that are acceptable for the diagnosis of delayed maturation. 
KITLG may be expressed in testes containing pre-IGCNU (Oosterhuis et al. 2011; Stoop et 
al. 2008).  
Study 2: Based on the general morphology, as assessed on HE staining, samples were 
categorized as (dysgenetic) testis, UGT, ovary, streak, or a combination of these. The 
sample was considered to be at risk for GCT development if either an in situ neoplastic 
lesion (GB or IGCNU) or one or more indices for pre-malignancy (UGT, OCT3/4-positive 





4.3.1. Study 1: Complete androgen insensitivity syndrome 
 
Influence of age, gonadal location at the time of gonadectomy, and expected level of AR 
activity on particular histological features was analyzed. The results were assessed using 
Mann-Whitney and Chi-square tests, as well as logistic, multivariate and linear 
regressions. Correlation between original gonadal location and AR activity was evaluated 
by a Chi-square test. Correlations between AR activity and age and between gonadal 
location and age were analyzed by a Mann-Whitney test. A value of p<0.05 was 
considered significant. All analyses were performed using SYSTAT 10.0. 
 
4.3.2. Study 2: 45,X/46,XY gonadal dysgenesis 
 
Results were analyzed with the SPSS software (version 15.0), comparison of categorical 












5.1. Study 1: Complete androgen insensitivity syndrome 
 
The original anatomical gonadal location was significantly dependent on expected AR 
activity (p<0.05). Whereas half of the gonads were originally situated in the abdominal 
cavity in patients with expected no residual activity, one gonad was labial and the rest were 
inguinal in patients with expected residual activity of AR. Labial or inguinal location of the 
gonads possibly contributed to relatively earlier clinical diagnosis and therefore earlier 
gonadectomy (p<0.01) in our study; however, age of gonadectomy did not differ 
significantly (p>0.05) between patients with and without residual activity of AR. 
Intertubular stroma appeared edematous (Figure 5A) mostly in younger patients whereas 
in the older individuals it was rather fibrotic (p<0.001) (Figure 5B). Combination of both 
edematous and fibrotic stromal changes within a single gonad was also observed, mainly 
in prepubertal patients. Areas of ovarian-like stroma (Figure 5C) were present in the 
gonads of one sibling pair (S4 and S9). Remarkably dilated lymphatic vessels (Figure 5D) 
were observed in 67% of gonads throughout the entire cohort. Hamartomatous nodules 
(Figure 5E), i.e., well circumscribed nodules composed of Sertoli cell-only tubules and 
Leydig cells in between the tubules, were observed in all pubertal and postpubertal 
patients (13-year-old and older), and therefore, their development was significantly 
dependent on age (p<0.001). Tubular atrophy presented as fibrosis of the tubules (Figure 
5F) was observed in 47% of patients older than 6 years of age and was significantly 
dependent on higher age (p<0.001). Diffuse Leydig cell hyperplasia (Figure 5G), which 
was present in all pubertal and postpubertal patients, was also dependent on older age 
(p<0.001). Scattered Sertoli cells with eosinophilic granules in the cytoplasm (Figure 5H), 






Figure 5: Different histopathological changes of the testis in CAIS, HE staining. A - 
edematous stroma (ES), 50x; B - fibrotic stroma (FS), 50x; C - ovarian-like stroma, 50x; 
D - dilation of lymphatic vessels, 50x; E - hamartomatous nodule (HN), 50x; F - fibrotic 
atrophy of the seminiferous tubule (arrow), 200x; G - Leydig cell hyperplasia (LCH), 
200x; H - eosinophilic granular changes of Sertoli cell cytoplasm (arrow), 400x; I - Sertoli 
cell nodule with central hyalin deposit, 400x; J - Sertoli cell nodules without hyaline 
deposit, 100x; K - sporadic lumen (L), 200x; L - multinucleate germ cell (arrow), 400x. 
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gonads, all in patients older than 9 years. Sertoli cell nodules, either with (Figure 5I) or 
without (Figure 5J) central hyaline deposits with partial calcification, were observed in 
almost 37% of patients, the youngest being 3 years old.  
In regard to signs of pubertal development, tubular lumen formation was evaluated and 
was not consistently present in any of the cases, although sporadic lumina (Figure 5K) 
were observed in the majority of the patients older than 9 years. Spermatogenesis was not 
encountered in any of the patients. 
At least one tubule with germ cells was found in 84 % of gonads. The number of tubules 
containing germ cells declined with age in the whole series (p<0.001). A significant 
difference in germ cell survival (p<0.05) between patients with and without expected  
residual AR activity in (post)pubertal age was observed. While the gonads of the patients 
without expected residual activity lacked germ cells altogether or contained only solitary 
tubules with germ cells, a considerable number of tubules with germ cells was identified in 
patients with expected residual AR activity (Figure 6). Multinucleated germ cells (Figure 
5L) were found in almost two-thirds of gonads in which some germ cells remained. 
Gonadal location (abdominal versus inguinal) was not an independent influential factor in 
any of the above-described features when corrected for age and expected AR activity.  
 
 
Figure 6: Germ cell survival in relation to age and expected level of AR activity. 
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Results of immunohistochemical analysis are represented in Table 6. Cells showing 
OCT3/4-positive staining were detected in 13/36 (35%) gonads from 9/19 (47%) patients. A 
certain continuum in their distribution within the tubules was observed with increasing age. 
More than 85% of the positive cells were situated in the center of the tubules in 4 young 
patients (age 3 months to 3 years), bilaterally in 2 of them (Figure 7A). Positively stained 
cells were few in all cases, had round nuclei, and were scattered throughout the whole 
gonad. They were TSPY-negative or only slightly positive (Figure 7B). All the gonads were 
negative for KITLG (Figure 7C). Thus, the histochemical and morphological pattern 
resembled that of fetal gonads (Honecker et al. 2004; Stoop et al. 2008). The findings were 
classified as delayed maturation in 3 patients who were older than 6 months. 
The earliest atypical features were identified in both of the gonads of a 6-year-old patient 
(S9). Up to 33% of the OCT3/4-positive cells were attached to the basal lamina. 
Distribution throughout the testis was patchy with regions of several adjacent positive 
tubules. The cells were both TSPY-negative and positive regardless the location within the 
tubules. Additionally, the cells were morphologically atypical, made obvious by the shape 
of the nuclei. Some nuclei were round, and others were irregular. Some of the areas with 
OCT3/4-positive cells were KITLG positive. However, there were also KITLG-negative 
tubules containing OCT3/4-positive cells. 
The changes were even more pronounced in the 4 oldest patients. OCT3/4-positive cells 
occupied one well circumscribed lobule in a 9-year-old patient (S10). Two-thirds of the 
cells were in contact with basal lamina (Figure 7D). The cells were very heterogeneous in 
morphology and staining pattern, again TSPY-positive or TSPY-negative in all locations 
(Figure 7E). KITLG expression was very strong in this case (Figure 7F). 
Several areas with OCT3/4-positive cells were encountered in two 15-year-old twins (S14, 
S15), in both gonads in one of them. Interestingly, these were virtually the only regions 
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with surviving germ cells (OCT3/4-positive and negative) within the whole gonads. More 
than 60% of OCT3/4-expressing cells were located at the periphery of the tubules, both 
positive and negative for TSPY. KITLG expression was identified in most, but not all, 
regions. 
Since the germ cells were very heterogeneous in morphology and expression within 
particular tubules and because normal spermatogonial cells (i.e., OCT3/4-negative and 
TSPY-positive) were often encountered in the same tubules as the atypical germ cells, a 
diagnosis of pre-IGCNU was made in patients S9, S10, S14 and S15.  
 
























































































































































Most GC only TSPY (+); OCT3/4 (+) GC 
are mostly TSPY (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are mostly TSPY (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are mostly TSPY (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are mostly TSPY (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are mostly TSPY (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are mostly TSPY (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are both TSPY (+) and (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are both TSPY (+) and (-) 
Most GC only TSPY (+); OCT3/4 (+) GC 
are both TSPY (+) and (-) 
Many GC only TSPY (+); OCT3/4 (+) GC 
are both TSPY (+) and (-) 
GC only in OCT3/4 (+) areas, some only 
TSPY (+); OCT3/4 (+) GC are both TSPY 
(+) and (-) 
GC only in OCT3/4 (+) areas, some only 
TSPY (+); OCT3/4 (+) GC are both TSPY 
(+) and (-) 
Many GC only TSPY (+); OCT3/4 (+) GC 





























































According to the above criteria, IGCNU was present in one gonad of a 15-year-old patient 
(S13). More than 90% of the OCT3/4-positive cells were attached to the basal lamina 
(Figure 7G). Clonal expansion of germ cells, which were uniform in OCT3/4 and TSPY 
Figure 7: Immunohistochemical staining of gonads positive for OCT3/4. A - delayed 
maturation - OCT3/4-positive germ cells (brown) all in the center of the tubules in a gonad of 
10-month-old individual (S2); B - same area as in A double-stained for OCT3/4 (orange) and 
TSPY (blue), which are not co-expressed within the same cells; C - same area as in A and B 
negative for KITLG; D - pre-IGCNU - most of the OCT3/4-positive germ cells are attached to 
the basal lamina in a gonad of 9-year-old individual (S10); E - detail of the same area as in D 
double-stained for OCT3/4 and TSPY, heterogeneity of the germ cells within tubules - cells 
are either positive for both OCT3/4 and TSPY (arrow) or only for TSPY (double arrow); F - 
same area as in E strongly positive for KITLG (red); G - IGCNU - almost all OCT3/4-positive 
germ cells are attached to the basal lamina in a gonad from 15-year-old individual (S13); H - 
same area as in G double-stained for OCT3/4 and TSPY - seminiferous tubule (IGCNU) with 
a uniform population of germ cells which are positive for OCT3/4 only (arrow); I - same area 




expression, was observed in several tubules (Figure 7H). The expression of TSPY in 
OCT3/4-positive germ cells was heterogeneous in other regions. KITLG expression was 
present in some, but not all, tubules with OCT3/4-positive germ cells (Figure 7I). Many 
tubules contained exclusively normal spermatogonia (OCT3/4-negative and TSPY-


















5.2. Study 2: 45,X/46,XY gonadal dysgenesis 
 
In 16/87 samples (18.3%) no gonadal tissue was found; hence, for these samples, the 
gonadal position could not be determined. In these cases (further referred to as 
“vanished”), the gonad was considered to have never developed, with as a consequence, 
regression of the gonadal anlagen.  
In the group with mild undervirilization, gonads were almost equally distributed over the 
scrotal (26.7%), inguinal (33.3%), and abdominal (33.3%) position; the remaining (6.7%) 
were vanished. In the group with ambiguous phenotype, the abdominal position was more 
frequent (59.1%), with 13.6% vanished gonads, whereas in the female phenotype group, if 
gonads were found (in 78.3%), they were invariably in the abdominal position (Figure 8A).  
Figure 8B shows the distribution of the gonadal differentiation patterns. Streak and 
dysgenetic testis represent the majority of cases, whereas UGT and a combination of UGT 
and testis are less frequent. Interestingly, the finding of ovarian follicles is very rare (1/87 
gonads, 1.1%), even in young 45,X/46,XY patients. No single patient presented with 
ovotesticular DSD. Within a streak, the stromal background displayed sometimes primitive 
tubule-like structures consisting of Sertoli cells, but without germ cells.   
In patients with mild undervirilization, most gonads had differentiated as testes (Figure 8C). 
In patients with an ambiguous phenotype, testicular differentiation was found in 54% of 
samples, whereas the other patterns had an almost equal distribution. Vanished and streak 
gonads represented almost all cases in phenotypically female patients. Testicular and 
ovarian differentiation were each found in only one sample.  
Scrotal gonads were all recognized as testes. Gonads in the inguinal position were mostly 




Figure 8: A - Location of the gonads in the different phenotypic groups. Samples with an 
unknown position contained no gonadal tissue on microscopic evaluation. B - Distribution 
of the encountered gonadal differentiation patterns. C - Distribution of gonadal 




gonads mostly presented as streak tissue (68.5%), but interestingly, also testis (20.5%) or 
a combination of testis+UGT (3.7%) is possible. An abdominal gonad with UGT 
differentiation was found in 5.6%, the only gonad with ovarian differentiation was in the 
abdominal position. 
Figure 9 shows representative examples of the gonadal differentiation patterns that were 
encountered in the 45,X/46,XY individuals included in the study.  
In our series, an in situ neoplasia was found in four different patients, and no invasive 
tumors were encountered (Table 7). One patient with an EMS of 7.5/12 received 
prophylactic gonadectomy of a right abdominal gonad, which on microscopic examination 
contained UGT with GB. On the left side, a scrotal testis was present. One patient with an 
EMS of only 1/12 received prophylactic surgery at the age of 1 year and was found to have 
UGT with GB in the left abdominal gonad; the right abdominal testis displayed no 
neoplastic features. One patient (EMS 1.5/12) had a GB in a severely dysgenetic testis in 
inguinal position, the right abdominal gonad was a streak, surgery was at 1 year. The last 
patient was diagnosed with Turner syndrome after work-up for delayed puberty. None of 
the treating physicians noticed any clitoral enlargement. However, when prophylactic 
gonadectomy was performed at the age of 16, a testis containing IGCNU was found in the 
right abdominal gonad, while the left specimen contained no gonadal tissue. 
Table 7: Summary of encountered tumors. 
 MU AP FP Total 
No tumor 14 21 45 80 
Tumor 1 (6.7%) 2 (8.7%) 1 (2.2%) 4 (4.8%) 
All tumors in our series were in situ germ cell neoplastic lesions, discovered after 
prophylactic gonadectomy. There were no invasive tumors. MU - Mild undervirilization; AP 






Figure 9: Representative examples of the gonadal differentiation patterns that were 
encountered in our series of patients with 45,X/46,XY mosacism, HE staining. A: Normal 
testis, 200x. B: Dysgenetic testis tubules, showing a thin basal lamina, an irregular 
tubular shape, and increased stromal background, 200x. C: Streak, 100x. D: 
Enlargement of C, clearly showing primitive testis cord-like structures (arrows), 200x. E: 
Ovarian follicles, encountered in only 1 gonad in our series, 200x. F and G: UGT, 200x. 




Fifteen gonads, including the four with an in situ neoplastic lesion, in 12 different patients, 
displayed premalignant characteristics. The three patients with bilateral premalignant 
lesions had an ambiguous phenotype. Individuals with an ambiguous phenotype had the 
highest prevalence of (pre)malignant characteristics (52.2%). In cases with mild 
undervirilization, the prevalence was lower but still considerable (13.3%). Phenotypically 
female individuals had a much lower prevalence (2.2%) (p < 0.001) (Table 8 and Figure 
10A). Inguinal gonads displayed (pre)malignant characteristics more frequently as 
compared to scrotal or abdominal gonads, however, this was not statistically significant (p 
= 0.09) (Figure 10B and Table 9).  
 
Table 8: Calculated risk for the development of a GCT in gonads from patients with 
45,X/46,XY mosaicism, taking into account the clinical phenotype. 
 
 
 MU AP FP Total X2 
No risk 13 11 45 69  
Risk 2 12 1 15  
 13% 52% 2.2% 18% P < 0.001 
MU - Mild undervirilization; AP -  Ambiguous phenotype; FP - Female phenotype. 
 
 
Table 9: Calculated risk for the development of a GCT in gonads from patients with 
45,X/46,XY mosaicism, taking into account the gonadal position.  
 Scrotal Inguinal Abdominal Unknown X2 
No risk 4 7 44 16  
Risk 1 4 9 0  







Figure 10: A - Presence of premalignant lesions or an in situ neoplasia in gonads from 
patients with 45,X/46,XY mosaicism categorized according to their clinical phenotype; B - 
Presence of premalignant lesions or an in situ neoplasia in gonads from patients with 






6.1. Study 1: Complete androgen insensitivity syndrome 
 
According to current knowledge, two major factors influence postnatal testicular 
development: the location of the gonad and the androgen action (Giwercman et al. 1989; 
Hannema et al. 2006). Some histopathological changes, e.g. hamartomatous nodules or 
Leydig cell hyperplasia, develop during puberty as a consequence of the almost or entirely 
absent activity of androgens in CAIS. Other features, such as a decrease in germ cells, 
multinucleated germ cells, tubular atrophy, anomalous intertubular stroma, hyaline 
deposits, or lymphatic dilation, occur early in childhood. Therefore, their development is 
probably caused by abnormal (inguinal or abdominal) location of the gonads, which 
commonly occurs in CAIS patients (Barthold et al. 2000). However, differences in the effect 
of inguinal versus abdominal position of the gonads were difficult to assess due to an 
unequal age distribution of the study group, with inguinal gonads being more frequent in 
younger patients.  
A positive impact of expected residual AR activity on the development of Wolffian duct 
structures and on the enlargement of seminiferous tubules after the onset of puberty in 
CAIS was described by Hannema and colleagues (Hannema et al. 2004; Hannema et al. 
2006). Additionally, we observed a significant positive effect on non-malignant germ cell 
survival after 13 years of age. Only single tubules containing germ cells were encountered 
in the gonads of patients with expected no residual activity of AR, whereas up to 34% of 
tubules of patients from the other group contained germ cells. No clear influence of 
expected residual AR activity was discovered on the other above-mentioned changes. 
The survival of germ cells with fetal features (i.e., OCT3/4-positive) and their progression 
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towards an invasive tumor in patients with CAIS are separate and very important issues. 
The level of risk for GCT development in CAIS remains a matter of debate. Manuel et al. 
estimated the cumulative risk to be 3.6% at 25 years of age and 33% at 50 years of age 
(Manuel et al. 1976). According to Deans et al., tumors occurred in 14% of adult patients 
based on historical literature (Deans et al. 2012). The risk was estimated to be 0.8% in 
another meta-analysis, but this estimation was mainly based on a group of patients in 
which gonadectomy was carried out during childhood (Cools et al. 2006a). In fact, the risk 
is very difficult to predict because the approaches to manage CAIS patients have 
continually changed over time. While older reports included many adult patients and 
mainly reported the presence of invasive GCT (Manuel et al. 1976; Morris and Mahesh 
1963; Rutgers and Scully 1991), more recent studies on pediatric patients refer to pre-
invasive lesions, i.e., IGCNU (Cools et al. 2005; Hannema et al. 2006). IGCNU is 
encountered mostly in pubertal or adolescent patients, however, the risk is calculated for 
entire patient groups that often include very young individuals in whom IGCNU has not had 
time to develop. Moreover, an intermediate stage between delayed maturation and adult 
type of IGCNU exists (Cools et al. 2005). Whether this lesion is predetermined to evolve 
into invasive cancer in all cases is unknown. In the general population fully developed 
IGCNU is estimated to progress to an invasive tumor in 50% of cases during 5 years, and 
its prevalence is similar to that of germ cell tumors, suggesting a 100% progression to 
invasiveness over time (Dieckmann and Skakkebaek 1999). 
A developmental continuum between germ cells with delayed maturation and IGCNU was 
observed in the study. OCT3/4-positive, TSPY-negative germ cells with round nuclei 
located in the center of the tubules, i.e., immature germ cells, were identified in at least 
one gonad in 4 patients whose age ranged between 3 months and 3.2 years. Cools et al. 
reported that some single OCT3/4-positive germ cells are present in testes of normal 
individuals 6 months of age or younger (Cools et al. 2005). Nevertheless, if the youngest 
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patient from our series is disregarded, 3 out of 7 patients (43%) between 6 months and 3.2 
years of age carried germ cells with delayed maturation. OCT3/4-positive germ cells with 
irregular nuclei attached to the basal lamina of the tubules, which in some cases were 
TSPY-positive and located within KITLG-positive areas, were identified in at least one 
gonad in 5 out of 11 patients (45%) older than 6 years. The lesion was classified as 
IGCNU in one case and as pre- IGCNU in the rest of the cases. Taken together, at least 
one gonad in 8 out of 18 (44%) patients older than 6 months contained OCT3/4-positive 
germ cells, which may have given rise to an invasive tumor.  
Regardless of whether we consider the proportion of the patients with (pre-)IGCNU among 
the older patients or the proportion of the patients older than 6 months with any kind of 
germ cell abnormality, the number of the gonads at risk is exceptionally high in comparison 
with other studies on pediatric patients. It is also high in comparison to cumulative risk for 
germ cell cancer in adult patients (33% at 50 years of age) estimated by Manuel (Cools et 
al. 2005; Hannema et al. 2006; Manuel et al. 1976). Such a high occurrence of atypical 
germ cells in this study may be incidental, but it may also indicate that not all abnormal 
germ cells will progress into an invasive tumor in CAIS patients. We suspect two possible 
mechanisms that may explain the difference between the high prevalence of germ cell 
anomalies in this series of pediatric/adolescent cases and the much lower prevalence of 
invasive tumors in adults. The first is an absolute loss of the abnormal germ cells in 
adulthood when the gonads would have been retained. The second is a failure of 
progression of the pre-invasive lesions into an invasive cancer. Both mechanisms may be 
caused by a lack of androgen action in CAIS, resulting in a low-androgen environment. 
This lack-of-androgen theory would correlate with a significantly higher risk for tumor 
development in PAIS patients (15% versus 0.8% in CAIS according to Cools et al.) (Cools 
et al. 2006a). Because we did not observe any significant differences in the persistence of 
OCT3/4-positive germ cells and KITLG expression in relation to the expected level of AR 
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activity among patients with CAIS, the residual activity of AR in CAIS is likely not powerful 
enough to achieve a similar effect on survival of abnormal germ cells and their progression 
into neoplasia as in PAIS. The result may be partly influenced by the relatively small 


















6.2. Study 2: 45,X/46,XY gonadal dysgenesis 
 
Tumor risk has been estimated at 15% in 45,X/46,XY individuals (Cools et al. 2006a). 
However, in clinical practice, histological examination of prophylactically removed gonads 
in Turner girls with 45,X/46,XY suggests a much lower incidence, whereas no data are 
available for boys with 45,X/46,XY. Specifically in this group, it is of interest to preserve 
gonads to allow endogenous hormone production, and therefore spontaneous puberty 
induction and maintenance.  
Categorization of gonadal differentiation patterns in 45,X/46,XY was difficult because they 
represent a continuum between two extremes (normal testis and normal ovary) rather than 
easily determinable separate entities, as is shown in Figure 9. Irrespective of the clinical 
phenotype, the finding of ovarian follicles was rare in 45,X/46,XY mosaicism (1/87 
samples), even from tissue removed at a very young age. This is in contrast to 
observations in 45,X and 45,X/46,XX gonads (Borgström et al. 2009). Likewise, ovotestes 
(defined as the co-presence of testis and ovarian tissue – including follicles- in one 
individual) were not encountered in our population, unlike in 46,XX/46,XY chimerism. 
Streak tissue (in our series present in 44% of samples) by definition does not contain germ 
cells, but also in dysgenetic testes and UGT, germ cells were scarce. Increased apoptosis 
of germ cells has been attributed to a defective micro-environment and impaired meiosis of 
aneuploid germ cells (Kocer et al. 2009).  
Tumor risk was significantly reflected by the clinical phenotype in this series (p < 0.001) 
allowing us to propose clinical guidelines (Table 10). The risk revealed to be very high 
(52%) in cases with an ambiguous phenotype. This group had the highest prevalence of 
UGT (20.8%), which has been recognized as the precursor lesion for GB (Cools et al. 
2006b) (Figure 8C). Moreover, testes, if present, were severely dysgenetic in this group, 
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and often contained immature OCT3/4-positive cells on the basal lamina, in contrast to 
patients with mild undervirilization, in whom UGT was less frequently observed (13.3%) 
and testes had attained a more mature stage with less pronounced shape irregularity of 
the tubules and more frequent loss of OCT3/4 expression in germ cells that had reached 
the basal lamina. Moreover, testes were more often in the scrotal position in this group 
(Figure 8A). Cryptorchidism is known as an independent risk factor for the development of 
GCT (Giwercman et al. 1987), which has been related to maturation delay of germ cells 
(Rajpert-De Meyts et al. 1998). This risk is probably higher in inguinal than in abdominal 
gonads, due to early apoptosis of germ cells in the latter position (Abouzeid et al. 2011). In 
this study, inguinal gonads revealed the highest tumor risk but this was not statistically 
significant, maybe due to small sample size (Figure 10B). 20% of 45,X/46,XY testes with 
spontaneous scrotal descent revealed premalignant characteristics but this number 
represents in fact only 1/5 gonads, from an individual with an EMS of 5.5, so belonging to 
ambiguous phenotype group. While interpreting these data, it has to be kept in mind that 
the differentiation patterns in these gonads and the clinical phenotypes of the patients 
were very heterogeneous, independently influencing tumor risk, in contrast to studies in 
patients with simple cryptorchidism, who all are normally virilized boys with well-
differentiated testes. In the phenotypically female group, tumor risk was low (2.2%). In this 
group, 46 gonads from 23 45,X/46,XY girls were examined, 44 of them were streak (so by 
definition devoid of germ cells) or had vanished (Table 5 and Figure 8C), explaining the 
low tumor risk. In one girl, who received gonadectomy at 10 years, ovarian follicles were 
found in one gonad (Figure 9E). Only 1/46 gonads (2.2%), from a 16 years old girl with 
Turner syndrome and a vanished gonad on the contra-lateral side, displayed testis 
differentiation, notably with IGCNU. 
The phenotype in all the patients revealed some degree of undervirilization. Thus, due to 
selection bias (no gonadal specimen were available from individuals who live 
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undiagnosed), we are unable to predict tumor risk in normal males with a 45,X/46,XY 
constitution, representing in fact the largest clinical group (Chang et al. 1990). However, 
from the findings as described above, it can be hypothesized that in these individuals, the 
risk is low, since the clinical picture of a normal EMS score and bilaterally descended 
testes suggest a (close to) normal testicular differentiation and maturation process. 
 
Table 10: Proposed guidelines for 45,X/46,XY gonadal dysgenesis. 
Mild undervirilization (EMS ≥ 7) 
       Orchidopexy 
       Regular self-examination and ultrasound from puberty onwards 
       Biopsy pre- and post puberty to assess tumor risk by specialized immunohistochemistry 
       In case of pre-malignant changes (OCT3/4-positive cells on the BL / expression of  
       KITLG / presence of UGT) or in situ neoplasia: gonadectomy 
Ambiguous genitalia (EMS < 7) 
       See guidelines for Mild undervirilization 
       Low threshold to perform gonadectomy 
Female phenotype 
       Elective gonadectomy (if patient is reluctant to gonadectomy: Consider to leave the  
       gonads in place) 
       Cryopreservation not indicated 
EMS - external masculinization score; OCT3/4 - octamer binding transcription factor 3/4; 


















Many histopathological changes in testis develop with increasing age and are mostly 
influenced by abnormal gonadal location and impaired androgen action in CAIS patients. 
An independent effect of inguinal versus abdominal position of the gonads was difficult to 
assess because inguinal gonads were present primarily in the youngest individuals. 
Expected residual AR activity contributes to better survival of the general germ cell 
population in (post)pubertal age; however, it did not seem to play an important role in the 
survival of OCT3/4-positive germ cells and KITLG overexpression and thus appears to be 
unrelated to a higher cancer risk in CAIS patients. Moreover, expected residual AR activity 
did not prevent the development of lack-of-androgen phenomena such as hamartomatous 
nodules and Leydig cell hyperplasia. The high percentage of patients with germ cell 
abnormalities in our study suggests that most of the lesions do not progress to IGCNU and 
subsequent invasive germ cell tumors in CAIS. The level of risk in such cases remains to 
be elucidated. We observed one case with IGCNU and no invasive tumors in our study. 
This finding, together with other studies on pediatric patients, supports the current practice 
of postponing prophylactic gonadectomy to an adult age. 
 
The data of Study 2 suggest that tumor risk in 45,X/46,XY patients is most pronounced in 
immature and/or poorly differentiated gonadal tissue, and that the degree of 
“testicularization” of the gonad (defined as the process of testicular development in its 
broadest sense) is reflected by the clinical phenotype. This knowledge can modify our 
clinical approach to the 45,X/46,XY patient, resulting in an individualized management with 
regard to tumor risk and gonadectomy. Future research and long-term follow-up of these 







Pacienti s poruchami pohlavního vývoje a zvýšeným rizikem rozvoje gonadálních nádorů 
ze zárodečných buněk většinou podstupují preventivní gonadektomii, která vţdy vede k 
nutnosti hormonální substituce, navíc někdy pacienty zbavuje fertility. Cílem práce bylo za 
pomoci detekce tkáňových nádorových markerů blíţe určit riziko rozvoje nádorů u 
kompletní formy syndromu necitlivosti k androgenům (CAIS) a 45,X/46,XY gonadální 
dysgeneze (GD) na základě funkčních či fenotypických charakteristik. 
Pomocí barvení hematoxylinem a eosinem a imunohistochemické detekce OCT3/4, TSPY 
a KITLG bylo vyšetřeno 37, respektive 36 tkáňových vzorků gonád 19 pacientů s CAIS a 
84 vzorků 47 pacientů s 45,X/46,XY GD. U první skupiny byly výsledky korelovány s 
polohou gonád a předpokládanou mírou aktivity androgenního receptoru. U druhé skupiny 
byla získaná data porovnána se stupněm virilizace zevního genitálu. 
Vliv polohy gonád (inguinální nebo abdominální) na histologické změny nelze u pacientů s 
CAIS nezávisle posoudit s ohledem na nerovnoměrnou distribuci vzhledem k věku. 
Předpokládaná zbytková aktivita androgenního receptoru má pozitivní efekt na přeţití 
obecné populace zárodečných buněk u (post)pubertálních pacientů, nehraje ale roli v 
rozvoji jejich atypických (neoplastických) změn. 
U pacientů s 45,X/46,XY GD byl prokázán významný vztah mezi rizikem rozvoje 
gonadálních nádorů a mírou virilizace zevního genitálu. Největší riziko mají pacienti s 
obojetným genitálem, podstatně méně jsou ohroţení pacienti s mírnou hypovirilizací a 
pacientky s fenotypem Turnerova syndromu. 
 
Klíčová slova: Kompletní forma syndromu necitlivosti k androgenům, 45,X/46,XY 






Patients with disorders of sex development with an increased risk for development of 
gonadal germ cell tumors mostly undergo prophylactic gonadectomy, that always leads to 
a need for hormonal substitution, and moreover, in some cases prevents fertility. The aim 
of the thesis was to better determine the risk for tumor development in relation to the 
functional and phenotypical characteristics in patients with complete form of androgen 
insensitivity syndrome (CAIS) and patients with 45,X/46,XY gonadal dysgenesis (GD).  
Hematoxiline and eosine staining and immunohistochemical detection of OCT3/4, TSPY 
and KITLG were used to assess 37 and 36 gonadal tissue samples of 19 CAIS patients, 
respectively, and 84 samples from 47 patients with 45,X/46,XY GD. The results were 
correlated with gonadal position and expected level of androgen receptor activity in the 
first group. The gained data were compared with level of virilization of external gentalia in 
the second group. 
Due to an unequal distribution in relation to the age in patients with CAIS, it was not 
possible to independently assess the influence of gonadal position (inguinal versus 
abdominal) on the histological gonadal changes. Expected residual androgen receptor 
activity has a positive effect on survival of general germ cell population but not on the 
development of the atypical (neoplastic) changes of the germ cells. 
A significant relation between tumor risk and level of virilization of external genitalia was 
demonstrated in patients with 45,X/46,XY GD. The risk is the highest in patients with 
ambiguous genitalia; in patients with mild undervirilization or patients with phenotype of 
Turner syndrome it is much lower. 
 
Key words: Complete androgen insensitivity syndrome, 45,X/46,XY gonadal dysgenesis, 
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